As of November 7, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of C4 Therapeutics, Inc. The largest reported stake is Soleus Capital Master Fund, L.P.'s, at 9.99%. 20 filings are on record since July 16, 2025 (Schedule 13G/A, February 12, 2026).
Sell to companies like C4 Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Lynx1 Capital Management LP · Sole voting: 0 · Shared voting: 15,423,691 · Sole dispositive: 0 · Shared dispositive: 15,423,691 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 11,383,696 · Sole dispositive: 0 · Shared dispositive: 11,383,696 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Squadron Master Fund LP · Sole voting: 0 · Shared voting: 7,600,000 · Sole dispositive: 0 · Shared dispositive: 7,600,000 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Morgan Stanley · Sole voting: 0 · Shared voting: 8,860,219 · Sole dispositive: 0 · Shared dispositive: 8,862,002 · SCHEDULE 13G/A, 2026-08-12
- · Reporting person: BlackRock, Inc. · Sole voting: 7,586,715 · Shared voting: 0 · Sole dispositive: 7,678,906 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-27
C4 Therapeutics, Inc. has 20 Schedule 13D or 13G filings on record since 2025-07-16. 8 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. | 9.99% | 10,361,860 | SCHEDULE 13G/A, 2026-02-12 | 2025-12-31 |
| Lynx1 Capital Management LP | 9.99% | 15,423,691 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| RA Capital Management, L.P. | 9.9% | 11,383,696 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Sirenia Capital Management LP | 9.9% | 23,505,000 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| 8% | 8,862,002 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 | |
| BlackRock, Inc. | 6.9% | 7,678,906 | SCHEDULE 13G, 2026-07-27 | 2026-06-30 |
| Squadron Master Fund LP | 6.9% | 7,600,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| BCLS II Equity Opportunities, LP | 6.25% | 6,060,000 | SCHEDULE 13G, 2025-10-24 | 2025-10-17 |
| Wasatch Advisors LP | 4.7% | 4,581,761 | SCHEDULE 13G/A, 2026-04-22 | 2026-03-31 |
| OrbiMed Capital LLC | 1% | 883,534 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Point72 Asset Management, L.P. | 0.2% | 169,096 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind C4 Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on C4 Therapeutics, Inc. and the records around it.
C4 Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Bain Capital Life Sciences Fund II, L.P. also filed stake reports on 2 other companies: Xilio Therapeutics, Inc. (May 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026), Stoke Therapeutics, Inc. (Aug 2026)
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), NextCure, Inc. (Aug 2026)
Watch C4 Therapeutics, Inc.
Get an email when C4 Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on C4 Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on C4 Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on C4 Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
21 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 0 | 15,423,691 | 0 | 15,423,691 | SCHEDULE 13G/A, 2026-08-14 |
| Weston Nichols | 0 | 15,423,691 | 0 | 15,423,691 | SCHEDULE 13G/A, 2026-08-14 |
| RA Capital Management, L.P. | 0 | 11,383,696 | 0 | 11,383,696 | SCHEDULE 13G/A, 2026-08-14 |
| Peter Kolchinsky | 0 | 11,383,696 | 0 | 11,383,696 | SCHEDULE 13G/A, 2026-08-14 |
| Rajeev Shah | 0 | 11,383,696 | 0 | 11,383,696 | SCHEDULE 13G/A, 2026-08-14 |
| RA Capital Healthcare Fund, L.P. | 0 | 11,383,696 | 0 | 11,383,696 | SCHEDULE 13G/A, 2026-08-14 |
| Morgan Stanley | 0 | 8,860,219 | 0 | 8,862,002 | SCHEDULE 13G/A, 2026-08-12 |
| Morgan Stanley Capital Services LLC | 0 | 8,718,000 | 0 | 8,718,000 | SCHEDULE 13G/A, 2026-08-12 |
| Morgan Stanley & Co. LLC | 0 | 134,047 | 0 | 134,047 | SCHEDULE 13G/A, 2026-08-12 |
| BlackRock, Inc. | 7,586,715 | 0 | 7,678,906 | 0 | SCHEDULE 13G, 2026-07-27 |
| Squadron Master Fund LP | 0 | 7,600,000 | 0 | 7,600,000 | SCHEDULE 13G/A, 2026-08-14 |
| Squadron Capital Management LLC | 0 | 7,600,000 | 0 | 7,600,000 | SCHEDULE 13G/A, 2026-08-14 |
| Matthew Sesterhenn | 0 | 7,600,000 | 0 | 7,600,000 | SCHEDULE 13G/A, 2026-08-14 |
| William Blank | 0 | 7,600,000 | 0 | 7,600,000 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies C4 Therapeutics, Inc. by CUSIP 12529R107 and gives its principal executive office as 490 ARSENAL WAY, SUITE 120, WATERTOWN, MA 02472 (SCHEDULE 13G/A, 2026-08-14).
What the percentages are based on
Due to the Beneficial Ownership Blockers listed in the Warrants, each Reporting Person's beneficial ownership percentage was 9.99% as of June 30, 2026.RA Capital Management, L.P., SCHEDULE 13G/A, 2026-08-14
All such shares of Common Stock in the aggregate represent beneficial ownership of approximately 6.9% of the Common Stock based on (i) 110,567,222 shares of Common Stock outstanding, $0.0001 par value per share, as of May 1, 2026, as reported by the Issuer on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026, plus (ii) 400,000 shares of Common Stock issuable upon exercise of the Options.Squadron Master Fund LP, SCHEDULE 13G/A, 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 2.5% | SCHEDULE 13G/A |
| 2025-08-07 | Morgan Stanley | 6.7% | SCHEDULE 13G/A |
| 2025-10-20 | Point72 Asset Management, L.P. | 9.9% | SCHEDULE 13G |
| 2025-10-24 | BCLS II Equity Opportunities, LP | 6.25% | SCHEDULE 13G |
| 2025-10-24 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G |
| 2025-11-13 | Wasatch Advisors LP | 6.8% | SCHEDULE 13G/A |
| 2025-11-14 | OrbiMed Capital LLC | 5% | SCHEDULE 13G/A |
| 2026-02-11 | Morgan Stanley | 9.3% | SCHEDULE 13G/A |
| 2026-02-12 | Soleus Capital Master Fund, L.P. | 9.99% | SCHEDULE 13G/A |
| 2026-02-17 | Lynx1 Capital Management LP | 7.3% | SCHEDULE 13G/A |
| 2026-02-17 | OrbiMed Capital LLC | 1% | SCHEDULE 13G/A |
| 2026-04-22 | Wasatch Advisors LP | 4.7% | SCHEDULE 13G/A |
| 2026-05-15 | Sirenia Capital Management LP | 9.9% | SCHEDULE 13G |
| 2026-05-15 | Point72 Asset Management, L.P. | 0.2% | SCHEDULE 13G/A |
| 2026-05-19 | Squadron Master Fund LP | 5% | SCHEDULE 13G |
| 2026-07-27 | BlackRock, Inc. | 6.9% | SCHEDULE 13G |
| 2026-08-12 | Morgan Stanley | 8% | SCHEDULE 13G/A |
| 2026-08-14 | Lynx1 Capital Management LP | 9.99% | SCHEDULE 13G/A |
| 2026-08-14 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G/A |
| 2026-08-14 | Squadron Master Fund LP | 6.9% | SCHEDULE 13G/A |
Questions about who owns C4 Therapeutics, Inc.
Who owns C4 Therapeutics, Inc.?
On this page, 8 holders' latest ownership filings report 5% or more of C4 Therapeutics, Inc.: Soleus Capital Master Fund, L.P. (9.99%, Schedule 13G/A, filed 2026-02-12), Lynx1 Capital Management LP (9.99%, Schedule 13G/A, filed 2026-08-14), RA Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-08-14), Sirenia Capital Management LP (9.9%, Schedule 13G, filed 2026-05-15) and Morgan Stanley (8%, Schedule 13G/A, filed 2026-08-12); 3 more are listed above.
Who are the largest shareholders of C4 Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of C4 Therapeutics, Inc. on this page are Soleus Capital Master Fund, L.P. (9.99%), Lynx1 Capital Management LP (9.99%) and RA Capital Management, L.P. (9.9%).
When did Soleus Capital Master Fund, L.P. buy into C4 Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Soleus Capital Master Fund, L.P. on this page is the Schedule 13G/A, filed 2026-02-12, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 20 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for C4 Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for C4 Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.